Doctors 'cautiously optimistic' about experimental Alzheimer's drug
An experimental Alzheimer's drug far outperformed placebo treatments in slowing the cognitive decline of Alzheimer's patients, Stat reported Wednesday, giving neurologists hope that an effective treatment for the disease is possible.
Patients who were given the drug, called BAN2401 and produced by Biogen and Eisai, "performed 30 percent better on a cognitive test than those getting placebo," Stat explained. The positive early returns may move the companies to approach the FDA for approval before conducting a larger study. But "there are caveats," Stat wrote: The drug's Phase 2 trial showed that the drug only outperformed placebo at its highest dose, and the highest dose was administered to just 161 patients. Moreover, the way Biogen and Eisai measured the drug's effectiveness is a proprietary method that has never been presented to the FDA before in an attempt to win approval.
Still, Stat called the results "unexpected and unprecedented." But it remains to be seen whether the companies will ultimately decide to operate a Phase 3 trial, or whether the FDA might be willing to lower the "traditionally high bar" it sets for approving Alzheimer's therapies, Stat wrote. "I'll remain cautiously optimistic," said Dr. Ronald Petersen, the director of the Mayo Clinic Alzheimer's Disease Research Center, but "you'd really want to see a Phase 3 to replicate those results." Read more at Stat.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Kimberly Alters is the news editor at TheWeek.com. She is a graduate of the Medill School of Journalism at Northwestern University.
-
The art world and motherhood: the end of a final taboo?
Talking Point Hettie Judah's new touring exhibition offers a 'riveting riposte' to old cliches
By Chas Newkey-Burden, The Week UK Published
-
'Musk's reliance on China draws rising scrutiny'
Today's Newspapers A roundup of the headlines from the US front pages
By The Week Staff Published
-
Biba: the story of a 'legendary emporium'
The Week Recommends Brand's 60th anniversary is being marked with retrospective celebrating the 'iconic shop's cultural importance'
By Adrienne Wyper, The Week UK Published
-
Puffed rice and yoga: inside the collapsed tunnel where Indian workers await rescue
Speed Read Workers trapped in collapsed tunnel are suffering from dysentery and anxiety over their rescue
By Sorcha Bradley, The Week UK Published
-
More than 2,000 dead following massive earthquake in Morocco
Speed Read
By Justin Klawans Published
-
Mexico's next president will almost certainly be its 1st female president
Speed Read
By Peter Weber Published
-
North Korea's Kim to visit Putin in eastern Russia to discuss arms sales for Ukraine war, U.S. says
Speed Read
By Peter Weber Published
-
Gabon's military leader sworn in following coup in latest African uprising
Speed Read
By Justin Klawans Published
-
Nobody seems surprised Wagner's Prigozhin died under suspicious circumstances
Speed Read
By Peter Weber Published
-
Western mountain climbers allegedly left Pakistani porter to die on K2
Speed Read
By Justin Klawans Published
-
'Circular saw blades' divide controversial Rio Grande buoys installed by Texas governor
Speed Read
By Peter Weber Published